Myocardial protection in beating heart cardiac surgery: I: Pre- or postconditioning with inhibition of es-ENT1 nucleoside transporter and adenosine deaminase attenuates post-MI reperfusion-mediated ventricular fibrillation and regional contractile dysfunction  by Abd-Elfattah, Anwar Saad et al.
E
T
/B
S
Evolving Technology/Basic Science Abd-Elfattah et alMyocardial protection in beating heart cardiac surgery: I: Pre- or
postconditioning with inhibition of es-ENT1 nucleoside transporter
and adenosine deaminase attenuates post-MI reperfusion-mediated
ventricular fibrillation and regional contractile dysfunctionAnwar Saad Abd-Elfattah, MS, PhD, FAHA, AFSTS,a Hamdy Aly, MD, PhD,b Scott Hanan, MD,a and
Andrew S. Wechsler, MD, FACScFrom th
monw
Schoo
adelp
Support
Abd-E
Disclosu
Receive
for pu
Address
ment
Broad
(E-ma
0022-52
Copyrig
doi:10.1
250Objective: To determine the role of the p-nitrobenzylthioinosine-sensitive equilibrative nucleoside transporter 1
(es-ENT1) in postmyocardial infarction reperfusion injury-mediated ventricular fibrillation and regional dys-
function. We used erythro-9 (2-hydroxy-3-nonyl)-adenine and p-nitrobenzylthioinosine to inhibit both adeno-
sine deamination and transport in a canine model of off pump acute myocardial infarction.
Methods:Anesthetized adult dogs (n¼ 37), instrumented to monitor the percentage of systolic segmental short-
ening and wall thickening using sonomicrometry, underwent 90 minutes of left anterior descending coronary
artery occlusion and 120 minutes of reperfusion. Myocardial coronary blood flow, adenosine triphosphate
pool, infarct size, and the incident of ventricular fibrillation and cardioversion were also measured. The dogs
received an intravenous infusion of the vehicle (control) or 100 mM of erythro-9 (2-hydroxy-3-nonyl)-adenine
and 25 mM p-nitrobenzylthioinosine before ischemia (preconditioning group) or just before reperfusion (post-
conditioning group).
Results: In the control group, adenosine triphosphate depletion was associated with the accumulation of more
inosine than adenosine during ischemia and washed out during reperfusion. Myocardial adenosine and inosine
were the major nucleosides in the pre- and postconditioning groups during ischemia and remained detectable
during reperfusion. In both groups, recovery of systolic segmental shortening andwall thickening and a reduction
in the incidence of ventricular fibrillation (P<.05 vs the control group) coincided with retention of myocardial
nucleosides. The infarct size in the 3 groups was not significantly different, independent of myocardial blood
flow during ischemia.
Conclusions: Preconditioning or postconditioning with erythro-9 (2-hydroxy-3-nonyl)-adenine/p-nitroben-
zylthioinosine significantly reduced the incidence of ventricular fibrillation and cardioversion and attenuated re-
gional contractile dysfunction mediated by postmyocardial infarction reperfusion injury. It is concluded that
p-nitrobenzylthioinosine-sensitive equilibrative nucleoside transporter 1 played a major role in these events.
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The Journal of Thoracic and Cardiovascular SurgReperfusion of the ischemic heart is a prerequisite interven-
tion for myocardial salvage and patient survival.1 In addi-
tion to preexisting ischemic injury, reperfusion of an
infarcted heart creates more aggressive conditions that trig-
ger a surge of free radicals and promote ventricular arrhyth-
mia and fibrillation. Therefore, targeting postischemic
reperfusion injury2 that occurs with thrombolytic therapy,
percutaneous coronary intervention, and coronary artery
bypass grafting (CABG) represents a major scientific and
clinical challenge and opportunity.
Ischemia depletes adenosine triphosphate (ATP), tran-
siently elevates adenosine, and progressively accumulates
inosine (Figure E1). On reperfusion, both adenosine and in-
osine are released from the ischemic cells by way of the
p-nitrobenzylthioinosine (NBMPR)-sensitive equilibrative
nucleoside transporter (es-ENT1), where they are converted
to hypoxanthine and xanthine. Both metabolites are sub-
strates for xanthine oxidase, catalyzing the formation ofery c July 2012
Abbreviations and Acronyms
ATP ¼ adenosine triphosphate
CABG ¼ coronary artery bypass grafting
EHNA ¼ erythro-9 (2-hydroxy-3-nonyl)-
adenine
es-ENT1 ¼ p-nitrobenzylthioinosine-sensitive
equilibrative nucleoside transporter 1
LAD ¼ left anterior descending
MI ¼ myocardial infarction
NBMPR ¼ p-nitrobenzylthioinosine
SS% ¼ segmental shortening
VFib ¼ ventricular fibrillation
WT% ¼ wall thickening
Abd-Elfattah et al Evolving Technology/Basic Sciencesuperoxide radicals on reperfusion.2 The es-ENT1 trans-
porter plays a major role in on- and off-pump canine models
of myocardial stunning.3-6 Specific binding sites of [3H]-
NBMPR7 and expression of the es-ENT1 gene and protein8
were identified in human and animal hearts, and the gene
has been cloned. Also, a knockout mouse model has
recently been developed9 that has demonstrated superior
outcomes after warm ischemia.10 However, the role of es-
ENT1 in reperfusion injury-mediated ventricular fibrilla-
tion after acute myocardial infarction (MI) in a large animal
model is unknown.
The present study was designed to test the hypothesis that
selective targeting of purine-mediated reperfusion injury
would lead to site-specific elevation and compartmentaliza-
tion of free adenosine and inosine in ischemic cells, provid-
ing localized protection against reperfusion-mediated
injury. Selective targeting of purine-mediated reperfusion
injury was achieved by inhibiting adenosine deaminase
with erythro-9 (2-hydroxy-3-nonyl)-adenine (EHNA) and
blocking adenosine transport with NBMPR. The results
demonstrated that pharmacologic pre- and postconditioning
with EHNA and NBMPR significantly improved the recov-
ery of function and reduced the incidence of ventricular fi-
brillation (VFib).E
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The biochemical reagents, EHNA and NBMPR, were obtained from
Sigma-Aldrich (St. Louis, Mo).
Animal Model
The experiments conformed to the Guidelines for the Care and Use
of Laboratory Animals published by the US National Institutes of Health
(publication no. 5377-3; available at http://www.nap.edu/catalog/5140.
html.
Surgical Procedures and Model of Acute MI
A total of 37 microfilaria-free adult dogs, of either sex and weighing
22.3  2 kg, were used in the present study. The dogs were anesthetizedThe Journal of Thoracic and Cawith an initial intravenous injection of 35mg/kg sodium pentobarbital (Ab-
bott Laboratories, Chicago, Ill) and intubated and ventilated using aBennett
MA1 respirator (Puritan-Bennett, Berkeley, Calif). Next, a median sternot-
omy was performed, and the heart was supported in a pericardial sling. The
anterior and posterior segments of the left ventricle were instrumented with
2 pairs of lead titanate zirconate piezoelectric crystals to monitor systolic
segmental shortening (SS%, 10 mm) and wall thickening (WT%, epicar-
dium to endocardium) using a pulse transit sonomicrometry system (Triton
Technology, San Diego, Calif). Millar transducers were placed intraven-
tricularly by way of the apex and into the carotid artery to monitor the
left ventricular and systemic pressures, respectively. The analog data
were digitized at 200 Hz and stored on a hard disk on a personal computer
and subsequently analyzed using interactive Crunch software developed in
our laboratory. Regional myocardial contractility and wall thickening were
measured at steady state conditions. The results were calculated as the per-
centage of change in the end-diastolic length in both SS% and WT% for
each beat (10–25 beats). The body and heart temperatures were maintained
at 37  1C. The right phrenic nerve was transected, and the sinoatrial
node was crushed and then paced at 150 bpm. A silastic snare was placed
around the left anterior descending (LAD) artery just before the first diag-
onal branch. Porcine-based heparin was intravenously injected (400 U/kg)
as an initial bolus followed by 200 U/kg/hr (Elkins-Sinn, Cherry Hill, NJ).
Arterial blood gases, pH, and hematocrit were routinely determined and
maintained (partial oxygen pressure, 100–140 mmHg; partial carbon diox-
ide pressure, 30–40 mm Hg; pH, 7.32–7.48; and hematocrit, about 30%).
Assessment of Adenine Nucleotide Pool Metabolism
Transmural Tru-Cut needle biopsy specimens (5–10 mg) were obtained
at baseline before and after drug administration, during LAD artery occlu-
sion, and after 120 minutes of reperfusion, as previously described.11
Regional Myocardial Blood Flow and Infarct Size
Coronary blood flow was measured using nonradioactive color micro-
spheres (NuFlow Hydron-Coat, Irvine, Calif), as previously described11,12
and published on line (see E-Methods).
Experimental Protocol
Myocardial blood flow, systolic SS%, WT%, and myocardial biopsy
were obtained at baseline, during LAD occlusion, and after reperfusion.
Matching measurements and biopsies were obtained from the nonischemic
posterior side of the left ventricle. The LAD coronary artery was snared for
90minutes. A single bolus of the vehicle (saline and 0.05% dimethylsulph-
oxide) or vehicle solution containing 100 mM EHNA and 25 mM NBMPR
(50 mL) was administered intravenously 5 minutes before LAD artery oc-
clusion (preconditioning group) or just before reperfusion (postcondition-
ing group).
Statistical Analysis
The data are presented as the mean  standard error of the mean. Se-
quential measurements were compared using analysis of variance for re-
peated measures using SAS (SAS Institute, Cary, NC). When significant
differences were detected between the groups’ pairs of mean values, they
were compared using Tukey’s post hoc tests. Differences were considered
significant if the probability value for comparison of least squares means
was less than 0.05; the F ratios are provided with the figures. The frequency
of VFib was analyzed using Fisher’s exact probability test.RESULTS
Exclusions
The exclusions are listed in Table E1. Dogswith significant
coronary blood flow (>20% of baseline 2.1 0.1 mL/min/g)rdiovascular Surgery c Volume 144, Number 1 251
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FIGURE 1. Effect of erythro-9 (2-hydroxy-3-nonyl)-adenine/p-nitroben-
zylthioinosine (EHNA/NBMPR) on (A) myocardial adenosine and (B) ino-
sine in a canine model of 90 minutes of left anterior descending (LAD)
artery occlusion and reperfusion showing statistically significant differ-
ences between groups with respect to (A) adenosine (P<.001, analysis
of variance, F ¼ 11.81; *P < .05 versus baseline and control group,
#P< .05 versus all other groups, analysis of variance; n ¼ 8 dogs/each
group) and (B) inosine (P< .01, 2-way analysis of variance, F ¼ 8.85;
*P<.05 versus baseline and control group, #P<.05 versus all other groups,
n ¼ 8 dogs/group). E/N, EHNA/NBMPR; PreC, preconditioning;
PostC, postconditioning; LV, left ventricle.
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(0–5%) were rejected from the study (7 of the 37 dogs).
All dogs (n¼ 8 in each group) survived to the end of reper-
fusion period, despite events of VFib during reperfusion.
Myocardial ATP
At baseline, the myocardial ATP levels were as follows:
control group, 30  3 nmol/mg protein; preconditioning
group, 28  3 nmol/mg protein; postconditioning group,
29  2 nmol/mg protein; and nonischemic posterior left
ventricular segment, 30  2 nmol/mg protein. Ninety min-
utes of LAD artery occlusion decreased the myocardial ATP
levels equally in all groups (>70%). The ATP level in the
control, preconditioning, and postconditioning groups was
4.8 2, 7.5 2, and 8.0 2 nmol/mg protein, respectively
(P<.01 vs baselines). The circumflex vascular bed had nor-
mal ATP levels. Unlike the control and postconditioning
groups, the ATP levels partially recovered in the precondi-
tioning group, to 11.3 3 and 13.3  2 nmol/mg protein at
the end of 30 and 120 minutes of reperfusion. respectively
(P<.05 vs baseline and other groups, analysis of variance,
F ¼ 5.87).
Myocardial Adenosine and Inosine
Adenosine and inosine were not detectable in the myo-
cardial tissue before LAD artery occlusion in any group
(Figure 1). At the end of 90 minutes of occlusion, a low
adenosine level was found in the control group, with
a marked increase in inosine (5.8  0.40 nmol/mg protein;
Figure 1, B). In the preconditioning group, both adenosine
and inosine progressively accumulated, reaching peaks at
90 minutes of LAD artery occlusion (7.8  0.7 and 3.3 
0.5 nmol/mg protein, respectively). Adenosine and inosine
declined but remained significantly detectable during reper-
fusion. Similar to the control group, adenosine was low in
the postconditioning group at the end of 90 minutes of
LAD artery occlusion (0.2  0.1 nmol/mg protein); inosine
was 7.3  0.6 nmol/mg protein. Unlike the control group,
inosine remained detectable during reperfusion in the post-
conditioning group during reperfusion.
Regional Systolic SS% and WT%
The baseline SS% and WT% in the control, precondi-
tioning, and postconditioning groups was 22%  3%,
20%  4%, and 19%  2% and 24%  5%, 19% 
3%, 21%  3%, and 22%  3%, respectively. At the on-
set of LAD artery occlusion, systolic SS% switched from
positive shortening to a negative paradoxical bulging
(Figure 2, A) and a concomitant profound wall thinning
(Figure 2, B) in all groups. In the control group, SS%
was25%  3% and WT% was77%  3% at 90 min-
utes of ischemia and remained depressed during reperfu-
sion (Figure 2, B). The change in WT% was almost
threefold greater than the change in SS% at the end of252 The Journal of Thoracic and Cardiovascular Surgischemia. In the preconditioning group, the SS% (18%
 2%) and WT% (50.3%  2%) were also similar to
those of the control group. A marked recovery was ob-
served in SS% in this group, reachingþ75%  2% and
þ78.4%  4% at 30 and 120 minutes of reperfusion, re-
spectively. The WT% in this group was less negative
(15%  2%) at 30 minutes of reperfusion than that at
the end of ischemia (55%  4%) and WT% had im-
proved at the end of reperfusion (25%  4%). In the post-
conditioning group, SS% at the end of ischemia was22%
 3% but had recovered toþ30%  3% andþ53%  3%
after 30 and 120 minutes of reperfusion, respectively. The
WT% changed from55%  3% at the end of ischemia
to a less negative36%  5% and then to positive thick-
ening (12%  3%) at 30 and 120 minutes of reperfusion,
respectively.ery c July 2012
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FIGURE 2. A, Effect of erythro-9 (2-hydroxy-3-nonyl)-adenine/p-nitro-
benzylthioinosine (EHNA/NBMPR) on (A) systolic segmental shortening
(SS%) and (B) wall thickening (WT%) in a canine model of 90 minutes
of left anterior descending (LAD) artery occlusion and reperfusion showing
statistically significant differences between groups with respect to (A) seg-
mental shortening (P<.01, analysis of variance, F¼ 8.3; *P<.05 vs. base-
line, #P<.05 vs control group, $P<.05 vs postischemic treatment group,
analysis of variance; n ¼ 8 dogs/group) and (B) wall thickening (P<.01,
analysis of variance, F ¼ 9.18; *P<.05 vs baseline, #P<.05 vs control
group, $P< .05 vs postischemic treatment group; n ¼ 8 dogs/group).
E/N, EHNA/NBMPR; PreC, preconditioning; PostC, postconditioning.
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FIGURE 3. Effect of erythro-9 (2-hydroxy-3-nonyl)-adenine/p-nitroben-
zylthioinosine (EHNA/NBMPR) on the incidence of (A) reperfusion-
mediated ventricular fibrillation (VFib) and (B) the number of defibrillation
attempt to resuscitate the heart in a canine model of 90 minutes of left an-
terior descending (LAD) artery occlusion and reperfusion showing statisti-
cally significant differences between groups (A, P < .05, analysis of
variance, F ¼ 4.02; *P<.05 vs control group, $P<.05 vs postischemic
treatment group, Fisher’s exact test; n¼ 8 dogs/group; and B, P<.05, anal-
ysis of variance, F ¼ 6.80; *P<.05 vs control group, $P<.05 vs postis-
chemic treatment group, Fisher’s exact test; n ¼ 8 dogs/group).
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SVentricular Fibrillation
The incidence of fibrillation was recorded during postis-
chemic reperfusion. VFib was more frequent at 25 to 30
minutes of reperfusion. All hearts that were resuscitated
with hand massage and electric cardioversions completed
the study (Figure 3, A). One or more episodes of VFib
that required cardioversion occurred in 6 of 8 hearts in theThe Journal of Thoracic and Cacontrol group, 2 of 8 in the preconditioning group, and 4
of 8 in the postconditioning group (P<.05, Fisher’s exact
probability test). The number of electric cardioversions
needed to achieve successful resuscitation (Figure 3, B)
was also lower in the EHNA/NBMPR-treated groups (pre-
conditioning, 1.8  0.8, and postconditioning, 1.5  0.3)
than in the control group (8.8  4; P<.05).Myocardial Blood Flow and Infarct Size
The myocardial blood flow before LAD artery occlusion
was 2.2  0.2, 2.1  0.1, and 2.01  0.2 mL/min/g in the
control, preconditioning, and postconditioning groups, re-
spectively (n ¼ 8/group). The coronary blood flow during
LAD artery occlusion was 0.14  0.05, 0.12  0.03, and
0.15  0.04 mL/min/g in the control, preconditioning,
and postconditioning groups, respectively (P¼NS). The is-
chemic area (risk area) relative to the total area of the left
ventricle was 39%  6%, 37%  4%, and 32%  5%rdiovascular Surgery c Volume 144, Number 1 253
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groups, respectively. The infarct size normalized to the
risk area was not significantly different among the 3 groups
(35%  5%, 24%  7%, and 28%  6% for the control,
preconditioning, and postconditioning groups, respectively;
P ¼ .08).
DISCUSSION
The hypothesis underlying the present study was that
ATP catabolites (adenosine and inosine), accumulating dur-
ing ischemia and released on reperfusion by way of the es-
ENT1, contribute to post-MI reperfusion injury-mediated
VFib and contractile dysfunction. A combination of
EHNA and NBMPR was used to modulate the adenosine
and inosine metabolism and compartmentalization during
ischemia and reperfusion. The unique feature of pre- and
postconditioning with EHNA/NBMPR is that their actions
are confined within the ischemic myocardium without af-
fecting nonischemic tissues. Because acute MI is irrevers-
ible, new modalities that target post-MI reperfusion injury
and improve functional recovery despiteMI represent a clin-
ical challenge and opportunity.
ATP depletion during LAD artery occlusion was similar
in all groups, suggesting that EHNA/NBMPR intervention
does not prevent ischemic injury, per se, but instead targets
reperfusion injury by modulating adenosine and inosine
metabolism and transport during ischemia and reperfusion.
Numerous investigators have characterized the phenomena
of classic ischemic preconditioning13 and postischemic pre-
conditioning14 in various models, demonstrating that en-
dogenous adenosine formation and release from ischemic
cells is required for activation of the adenosine receptor sub-
types that mediate the anti-infarction signaling mecha-
nisms.15,16 Because NBMPR blocks the release and
uptake of adenosine and inosine (Ki ¼ 0.05 nM), the
entrapped intracellular adenosine is presumably not
accessible to the membrane surface adenosine receptors.
This could explain, in part, the insignificant reduction in
the infarct size observed in the preconditioning and
postconditioning groups. In the postconditioning group,
delaying the administration of EHNA/NBMPR to the end
of ischemia but before reperfusion also entrapped more
inosine than adenosine and was associated with improved
recovery of regional function and a reduced incidence of
VFib but not infarct size. In isolated perfused rabbit heart
preparations, Walsh et al17,18 have demonstrated that
pretreatment with EHNA/NBMPR not only prevented
adenosine and inosine release during hypoxia but also
abolished the infarct size-limiting effects of ischemic pre-
conditioning. Because preexisting MI increases the risk of
VFib and contractile failure, pre- and postconditioning
with EHNA/NBMPR would improve the outcomes with
post-MI reperfusion. Pharmacologic pre- plus postcondi-
tioning is the more relevant clinical application in targeting254 The Journal of Thoracic and Cardiovascular Surgreperfusion injury after MI than ischemic pre- and postcon-
ditioning. The MI induced by LAD coronary artery occlu-
sion in dogs is usually more pronounced toward the
endocardium than toward the mid- and epicardium; a phe-
nomenon known as ‘‘wave front.’’ This could explain, in
part, the improved recovery of regional shortening moni-
tored by sonocrystals placed between the epi- and midcar-
dium, despite endocardial infarction. This also might have
affected the recovery of transmural wall thickening moni-
tored by crystals placed between the epi- and endocardium.
The mechanisms by which EHNA/NBMPR improve
contractile recovery and attenuate fibrillation could be re-
lated, in part, to attenuation of free radical production de-
rived from adenosine and inosine catabolism during
reperfusion. The partial recovery of ATP during reperfusion
in the preconditioning group has confirmed that adenosine
was mainly localized in an intracellular compartment. Be-
cause preconditioning with EHNA/NBPR entraps high
levels of adenosine, we postulated that the entrapped intra-
cellular adenosine triggers unknown intracellular mecha-
nisms of protection. Recently, Grube et al19 reported
localization of the adenosine A2B receptor inside cardiac
cells. In an accompanying study,20 we demonstrated that
8-cyclopentyl-1,3-dipropyl-xanthine, selective A1 receptor
antagonist, or 8-(p-sulfophenyl)theophyline, the nonselec-
tive adenosine A1, A2A, A2B, A3 receptor antagonist,
slightly reduced but did not abolish EHNA/NBMPR-
mediated cardiac functional recovery. Xi et al21 and Urma-
liya et al22 have recently demonstrated that activation of the
adenosine A1 receptor is dependent on cooperative activa-
tion of both A2A and A3 receptors. However, the role of
the A2A, A2B, and A3 receptors in EHNA/NBMPR-
mediated protection needs to be elucidated with selective
agonists and antagonists.
In clinical settings, emergent thrombolytic therapy, per-
cutaneous coronary intervention, and/or CABG are per-
formed to restore blood perfusion to the ischemic
myocardium as early as possible. In these cases, we believe
that pre- and postconditioning with EHNA/NBMPR might
not reduce preexisting MI but targets post-MI–mediated
complications associated with reperfusion injury. These
drugs could be infused intravenously or by intracoronary
administration using the transcatheters before coronary in-
tervention. Previous clinical trials have demonstrated the
safety and efficacy of exogenous adenosine as an adjunct
to cold cardioplegia during CABG23 and as an adjuvant to
thrombolytic therapy in the Acute Myocardial Infarction
Study of Adenosine (AMISTAD) trials.24 In the latter trial,
a reduction in the infarct size was observed in the early, but
not late, MI and only at a high dose of adenosine (70 mg/mL/
min for 3 hours). However, the over all mortality was not af-
fected by adenosine therapy. Because adenosine has a short
half life in humans and animals (seconds), higher doses of
adenosine were used to reach pharmacologic efficacy.ery c July 2012
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wanted free radical substrates for the vascular xanthine ox-
idase. Therefore, EHNA would prolong the half life of
exogenous adenosine and reduce the dose of adenosine in
future clinical trials. Our intervention introduces the con-
cept of ‘‘global myocardial protection’’ during off-pump
beating heart CABG surgery without hypothermia, cardio-
plegic arrest on pump. The infusion of EHNA/NBMPR in
a model of the off-pump beating heart provides site-
specific protection at the ischemic vascular bed and wher-
ever oxidative stress might occur during surgery. Targeting
post-MI reperfusion injury with EHNA/NBMPR has impor-
tant clinical potential in cases of post-MI thrombolytic ther-
apy, stenting, and CABG.
Study Limitations
The present study had the obvious experimental model
limitations that must be considered, including species-,
age-, and model-related differences. The issue of the
species-dependent presence of xanthine oxidase remains
debatable. However, it is believed that the porcine heart re-
sembles the human anatomy and coronary distribution.
Also, some concerns have been recognized regarding the
utility of color microspheres to measure myocardial blood
flow because of the loss of microspheres and the yield of
color recovery during extraction of microspheres and colors
and analysis. Another limitation was the use of load-
dependent estimates of regional function. Echocardiogra-
phy would be more appropriate to monitor global function
in the presence of a significant MI. Finally, the doses of
EHNA and NBMPR were used according to our previous
reports3,4 and were greater than the Ki values (0.05 nM).
The dose–response relationship was not intended in this
canine model of MI. The timing of the administration of
EHNA/NBMPR was considered to target post-MI reperfu-
sion injury compared with before MI treatment.
E-Limitations are published on line.
CONCLUSIONS
The es-ENT1 transporter plays a crucial role in purine-
mediated reperfusion injury and that pharmacologic
targeting of this transporter attenuates VFib and regional
dysfunction in the presence of MI. Pre- and postcondition-
ing with EHNA/NBMPR in amodel of beating heart cardiac
surgery has obvious clinical relevance to the setting of elec-
tive or emergent thrombolytic therapy, percutaneous coro-
nary intervention, and CABG.
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E-METHODS
Surgical Procedures and Model of Acute MI
A total of 37 microfilaria-free adult dogs, of either sex and weighing
22.3  2 kg, were used in the present study. The dogs were anaesthetized
with an intravenous injection of 35 mg/kg sodium pentobarbital (Abbott
Laboratories, Chicago, Ill), intubated, and ventilated using a Bennett
MA1 respirator (Puritan-Bennett, Berkeley, Calif). Additional doses of
10 mg/kg sodium pentobarbital were injected as needed to maintain anes-
thesia. A median sternotomy was performed, and the heart was supported
in a pericardial sling. The anterior (ischemic) and posterior (nonischemic)
segments of the left ventricle were instrumented with 2 pairs of lead
titanate zirconate piezoelectric crystals to monitor systolic segmental
shortening and systolic wall thickening using a pulse transit sonomicrom-
etry system (Triton Technology, San Diego, Calif). Micromanometer
balloon-tipped catheters (Millar Instruments, Houston, Tex) were placed
intraventricularly by way of the apex and into the carotid artery to monitor
the left ventricular and systemic pressures, respectively. The analog data
were digitized at 200 Hz and stored on a hard disk on a personal com-
puter. Subsequent analysis was performed using interactive Crunch soft-
ware developed in our laboratory. Regional myocardial contractility and
wall thickening were measured at varying preloads, as previously descri-
bed.E1 The body temperature was maintained constant with heating pads,
and the myocardial temperature was kept at 37  1C. A fluid supple-
ment was given as an intravenous drip. A silastic snare was placed around
the left anterior descending artery just before the first diagonal branch.
The right phrenic nerve was transected to eliminate diaphragmatic con-
tractions. The sinoatrial node was crushed, and the heart atrially paced
at 150 bpm using a Medtronic 5880A pacemaker (Medtronic, Minneapo-
lis, Minn). The rationale for electrical pacing of hearts is to minimize
variations in the heart rates among dogs of the same group and between
groups. Porcine-based heparin was injected intravenously (400 U/kg) as
an initial bolus followed by 200 U/kg/hr (Elkins-Sinn, Cherry Hill, NJ).
Arterial blood gases, pH, and hematocrit were routinely determined and
maintained (partial oxygen pressure, 100–140 mm Hg; partial carbon
dioxide pressure, 30–40 mm Hg; pH, 7.32–7.48; and hematocrit, about
30%).
Assessment of Adenine Nucleotide Pool Metabolism
Myocardial adenine nucleotides (adenosine triphosphate [ATP], adeno-
sine diphsophate, and adenosine monophosphate), adenine nucleosides
(adenosine and inosine), purine bases (hypoxanthine and xanthine), and
nicotinamide adenine dinucleotide (NADþ) were determined at baseline,
during 90 minutes of left anterior descending artery occlusion and 120
minutes of reperfusion. Transmural Tru-Cut needle (Travenol Laboratories,
Deerfield, Ill) biopsy specimens (5–10mg)were obtained at baseline before
and after drug administration. Serial biopsies were obtained during 90 min-
utes of normothermic ischemia and 120minutes of reperfusion. Each biopsy
was immediately frozen and stored in liquid nitrogen (196C). Each biopsy
specimen was extracted, neutralized, and analyzed using high-performance
liquid chromatography, as previously described,E2,E3 and the values were
normalized per milligram protein.
Measuring Coronary Flow With Colored
Microspheres
Measurements of regional coronary flow were performed as previously
describedE4 before and during ischemia. Fluorescent-labeled microspheres
(15 mm in diameter) were injected into the left atrium of the anesthetized
dogs, and reference blood samples were simultaneously withdrawn from
a femoral artery. At the end of each study, each heart was weighed and
transmurally cubed and divided into the epicardium and endocardium
and accurately weighed. The tissue samples and reference blood samples
were digested with potassium hydroxide and filtered, and the fluorescent
dye was extracted with dimethylformamide as a solvent. The fluorescence
of each sample was determined for each color using an automated spectro-
photometer. The coronary blood flow was expressed as the mean milliliters
per minute per gram of tissue weight of the transmural sections of the
myocardium.
Tissue Histologic Examination
Tissue samples (200–400 mg) were obtained at the end of each study
from the ischemic and nonischemic segments of the left ventricle and fixed
in glutaraldehyde and prepared for thin sectioning and electron microscope
analysis, as previously described by Hayte. The samples were analyzed by
a histologist (H.A.) who was unaware of the groups.
Myocardial NADþ
Figure 4 shows the effects of acute myocardial ischemia and reperfusion
on tissue NADþ in all groups. At baseline, all groups had similar NADþ
levels. The decline in myocardial NADþwas more pronounced (50%) in
the untreated control group (from 3.7  0.3 to 1.8  0.3 nmol/mg protein,
about a 50% reduction from baseline) during ischemia and continued to de-
cline to 1.4 0.2 and 1.2 0.2 nmol/mg protein (59% and 63%) during 30
and 120 minutes of reperfusion. In the preconditioning and postcondition-
ing groups, the NADþ levels were maintained during ischemia and during
reperfusion (Figure E2).
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FIGUREE1. Role of adenine nucleosides metabolism and transport by way of es-NT1 (compartmentalization) in purine-mediated post-myocardial infarc-
tion reperfusion injury. The figure illustrates purine metabolism and compartmentalization in relation to ischemic and reperfusion injury in the untreated
control group (A). Ischemia is associated with intracellular adenosine triphosphate (ATP) depletion. Sympathetic stimulation at the onset of ischemia results
in neurotransmitter and ATP co-release, elevating extracellular ATP. Ecto- and endo-50-nucleotidase (endo) and adenosine deaminase continue breaking
down ATP and adenosine monophosphate (AMP) during ischemia to adenosine in the intracellular and extracellular compartments. Adenosine is rapidly
deaminated to inosine by adenosine deaminase. Extracellular inosine is converted by inosine phosphorylase (IPLase) to hypoxanthine, and the latter is ox-
idized to xanthine and superoxide radicals during cardiac ischemia and reperfusion. Intracellular inosine and the remaining adenosine are rapidly released on
reperfusion by way of the p-nitrobenzylthioinosine (NBMPR)-sensitive adenine nucleoside transporter-1 (es-ENT1), allowing abrupt formation of hypoxan-
thine, xanthine, and free radicals. The effect of preischemic treatment with EHNA/NBMPR of purine metabolism and compartmentalization is depicted in
part B. Adenosine is maintained inside and outside cells. C, Effect of MI postconditioning with EHNA/NBMPR. Intracellular inosine is the major end prod-
uct of ATP depletion during ischemia. Similar to the control group, noncardiac ATP is broken down to xanthine, producing free radicals in the circulation.
Infusion of EHNA/NBMPR after MI but before releasing the left anterior descending coronary artery occlusion allowed entrapment of intracellular inosine,
limiting the reperfusion injury mediated by free radicals. ADP, Adenosine diphosphate; AMP, adenosine monophosphate; ecto-50NTDase, 50-nucleotidase;
es-ENT1, equilibrative p-nitro-benzylthioinosine (NBMPR)-sensitive adenine nucleoside transport 1; A1R, adenosine receptor 1; IPLase, inosine phosphor-
ylase; XO, xanthine oxidase; O2, molecular oxygen;
.O2, superoxide radical. The font size reflects the amount of purine at ischemia or reperfusion.
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FIGURE E2. Effect of erythro-9 (2-hydroxy-3-nonyl)-adenine/p-nitrobenzylthioinosine (EHNA/NBMPR) on myocardial nicotinamide adenine dinucle-
otide (NADþ) in a canine model of 90 minutes left anterior descending (LAD) atery occlusion and reperfusion. There was statistical significance between
groups (P<.05, 2-way analysis of variance). *P<.05 vs baseline and control group. #P<.05 vs post-ischemic treatment group, analysis of variance, n¼ 8
dogs/each group. LV, Left ventricle.
TABLE E1. Reasons for excluding dogs from the study
Reason
Control
group (n)
EHNA/NBMPR group (n)
Before
ischemia
After
ischemia
Fatal anesthesia 1 0 1
Baseline hypotension or
tachycardia (>200 bpm)
1 2 0
Significant collateral flow
(>20% during LAD
occlusion)
3 2 2
Total excluded dogs (n) 5 (31.3%) 4 (36.4%) 3 (27.3%)
Total dogs possible (n) 13 11 11
Dogs used (n) 8 (61.5%) 8 (66.7%) 8 (72.7%)
EHNA/NBMPR, Erythro-9 (2-hydroxy-3-nonyl)-adenine; NBMPR, p-nitrobenzylth-
ioinosine; LAD, left anterior descending (artery).
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